Gillian Bates
#67,027
Most Influential Person Now
British biologist
Gillian Bates's AcademicInfluence.com Rankings
Gillian Batesbiology Degrees
Biology
#4431
World Rank
#6603
Historical Rank
Genetics
#912
World Rank
#1008
Historical Rank
Download Badge
Biology
Gillian Bates's Degrees
- Bachelors Biology University of Oxford
Similar Degrees You Can Earn
Why Is Gillian Bates Influential?
(Suggest an Edit or Addition)According to Wikipedia, Gillian Patricia Bates FMedSci FRS is a British biologist. She is distinguished for her research into the molecular basis of Huntington's disease and in 1998 was awarded the GlaxoSmithKline Prize as a co-discoverer of the cause of this disease. As of 2016, she is Professor of Neurogenetics at UCL Institute of Neurology and the co-director of UCL Huntington's Disease Centre.
Gillian Bates's Published Works
Published Works
- A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes (1993) (7826)
- Exon 1 of the HD Gene with an Expanded CAG Repeat Is Sufficient to Cause a Progressive Neurological Phenotype in Transgenic Mice (1996) (3026)
- Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. (1997) (2717)
- Formation of Neuronal Intranuclear Inclusions Underlies the Neurological Dysfunction in Mice Transgenic for the HD Mutation (1997) (2223)
- Huntingtin-Encoded Polyglutamine Expansions Form Amyloid-like Protein Aggregates In Vitro and In Vivo (1997) (1272)
- The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. (2000) (1068)
- Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease (2003) (853)
- Self-assembly of polyglutamine-containing huntingtin fragments into amyloid-like fibrils: implications for Huntington's disease pathology. (1999) (673)
- Huntington disease (2015) (580)
- A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease (2008) (559)
- A novel gene encoding an integral membrane protein is mutated in nephropathic cystinosis (1998) (545)
- Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human huntington disease gene. (1998) (527)
- Global changes to the ubiquitin system in Huntington's disease (2007) (503)
- Huntingtin and the molecular pathogenesis of Huntington's disease (2004) (485)
- Huntingtin aggregation and toxicity in Huntington's disease (2003) (482)
- Intranuclear Neuronal Inclusions in Huntington's Disease and Dentatorubral and Pallidoluysian Atrophy: Correlation between the Density of Inclusions andIT15CAG Triplet Repeat Length (1998) (443)
- Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease. (2000) (441)
- Selective Discrimination Learning Impairments in Mice Expressing the Human Huntington's Disease Mutation (1999) (405)
- Abnormal Synaptic Plasticity and Impaired Spatial Cognition in Mice Transgenic for Exon 1 of the Human Huntington's Disease Mutation (2000) (401)
- Aberrant splicing of HTT generates the pathogenic exon 1 protein in Huntington disease (2013) (395)
- IKK phosphorylates Huntingtin and targets it for degradation by the proteasome and lysosome (2009) (369)
- Mitochondrial dysfunction and free radical damage in the Huntington R6/2 transgenic mouse (2000) (347)
- Progressive decrease in chaperone protein levels in a mouse model of Huntington's disease and induction of stress proteins as a therapeutic approach. (2004) (334)
- A candidate for the cystic fibrosis locus isolated by selection for methylation-free islands (1987) (331)
- Instability of highly expanded CAG repeats in mice transgenic for the Huntington's disease mutation (1997) (324)
- Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage. (2007) (322)
- SIRT2 inhibition achieves neuroprotection by decreasing sterol biosynthesis (2010) (319)
- Formation of polyglutamine inclusions in non-CNS tissue. (1999) (299)
- Impaired Glutamate Uptake in the R6 Huntington's Disease Transgenic Mice (2001) (298)
- Proteolysis of Mutant Huntingtin Produces an Exon 1 Fragment That Accumulates as an Aggregated Protein in Neuronal Nuclei in Huntington Disease* (2010) (292)
- Systematic behavioral evaluation of Huntington's disease transgenic and knock-in mouse models (2009) (292)
- Dysfunction of the Cholesterol Biosynthetic Pathway in Huntington's Disease (2005) (276)
- Environmental enrichment slows disease progression in R6/2 Huntington's disease mice (2002) (270)
- A potent small molecule inhibits polyglutamine aggregation in Huntington's disease neurons and suppresses neurodegeneration in vivo. (2005) (269)
- Structure and expression of the Huntington's disease gene: Evidence against simple inactivation due to an expanded CAG repeat (1994) (269)
- Altered neurotransmitter receptor expression in transgenic mouse models of Huntington's disease. (1999) (249)
- SH3GL3 associates with the Huntingtin exon 1 protein and promotes the formation of polygln-containing protein aggregates. (1998) (232)
- UBQLN2 Mediates Autophagy-Independent Protein Aggregate Clearance by the Proteasome (2016) (227)
- Proteomic profiling of plasma in Huntington's disease reveals neuroinflammatory activation and biomarker candidates. (2007) (220)
- Histone deacetylase inhibitors as therapeutics for polyglutamine disorders (2006) (214)
- Ultrastructural localization and progressive formation of neuropil aggregates in Huntington's disease transgenic mice. (1999) (211)
- DNA instability in postmitotic neurons (2008) (192)
- Polyglutamine expansion of huntingtin impairs its nuclear export (2005) (189)
- The huntingtin interacting protein HIP1 is a clathrin and alpha-adaptin-binding protein involved in receptor-mediated endocytosis. (2001) (180)
- History of genetic disease: The molecular genetics of Huntington disease — a history (2005) (178)
- Exendin-4 Improves Glycemic Control, Ameliorates Brain and Pancreatic Pathologies, and Extends Survival in a Mouse Model of Huntington's Disease (2009) (169)
- Are neuronal intranuclear inclusions the common neuropathology of triplet-repeat disorders with polyglutamine-repeat expansions? (1998) (168)
- The Hdh Q150/Q150 knock-in mouse model of HD and the R6/2 exon 1 model develop comparable and widespread molecular phenotypes (2007) (168)
- Altered chromatin architecture underlies progressive impairment of the heat shock response in mouse models of Huntington disease. (2011) (165)
- Minocycline and doxycycline are not beneficial in a model of Huntington's disease (2003) (165)
- Biomarkers for neurodegenerative diseases (2005) (165)
- The Huntington's disease candidate region exhibits many different haplotypes (1992) (165)
- Identical oligomeric and fibrillar structures captured from the brains of R6/2 and knock-in mouse models of Huntington's disease (2009) (160)
- Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice (2006) (147)
- SAHA Decreases HDAC 2 and 4 Levels In Vivo and Improves Molecular Phenotypes in the R6/2 Mouse Model of Huntington's Disease (2011) (147)
- The pathogenic exon 1 HTT protein is produced by incomplete splicing in Huntington’s disease patients (2017) (145)
- HDAC4 Reduction: A Novel Therapeutic Strategy to Target Cytoplasmic Huntingtin and Ameliorate Neurodegeneration (2013) (145)
- Progressive alterations in the hypothalamic-pituitary-adrenal axis in the R6/2 transgenic mouse model of Huntington's disease. (2006) (144)
- HTT-lowering reverses Huntington's disease immune dysfunction caused by NFκB pathway dysregulation. (2014) (141)
- Formation of Polyglutamine Inclusions in a Wide Range of Non-CNS Tissues in the HdhQ150 Knock-In Mouse Model of Huntington's Disease (2009) (141)
- Standardization and statistical approaches to therapeutic trials in the R6/2 mouse (2003) (139)
- Transgenic models of Huntington's disease. (1999) (137)
- Targeting H3K4 trimethylation in Huntington disease (2013) (136)
- Increased metabolism in the R6/2 mouse model of Huntington’s disease (2008) (134)
- The S/T-Rich Motif in the DNAJB6 Chaperone Delays Polyglutamine Aggregation and the Onset of Disease in a Mouse Model. (2016) (132)
- Mutant huntingtin fragmentation in immune cells tracks Huntington's disease progression. (2012) (130)
- Sequence comparison of human and yeast telomeres identifies structurally distinct subtelomeric domains. (1997) (130)
- Comparative sequence analysis of the human and pufferfish Huntington's disease genes (1995) (130)
- SIRT2 Ablation Has No Effect on Tubulin Acetylation in Brain, Cholesterol Biosynthesis or the Progression of Huntington's Disease Phenotypes In Vivo (2012) (128)
- Treating the whole body in Huntington's disease (2015) (122)
- Suppression of protein aggregation by chaperone modification of high molecular weight complexes (2012) (121)
- Contribution of nuclear and extranuclear polyQ to neurological phenotypes in mouse models of Huntington's disease. (2005) (117)
- Sensitive biochemical aggregate detection reveals aggregation onset before symptom development in cellular and murine models of Huntington’s disease (2007) (115)
- Trinucleotide repeat expansions and human genetic disease. (1994) (112)
- Centrosome disorganization in fibroblast cultures derived from R6/2 Huntington's disease (HD) transgenic mice and HD patients. (2001) (112)
- A brain-permeable small molecule reduces neuronal cholesterol by inhibiting activity of sirtuin 2 deacetylase. (2011) (109)
- Complex alteration of NMDA receptors in transgenic Huntington's disease mouse brain: analysis of mRNA and protein expression, plasma membrane association, interacting proteins, and phosphorylation (2003) (109)
- Proteasome impairment does not contribute to pathogenesis in R6/2 Huntington's disease mice: exclusion of proteasome activator REGgamma as a therapeutic target. (2006) (107)
- Metabolic characterization of the R6/2 transgenic mouse model of Huntington's disease by high-resolution MAS 1H NMR spectroscopy. (2006) (107)
- The importance of integrating basic and clinical research toward the development of new therapies for Huntington disease. (2011) (105)
- Hdac6 Knock-Out Increases Tubulin Acetylation but Does Not Modify Disease Progression in the R6/2 Mouse Model of Huntington's Disease (2011) (100)
- SUMO-2 and PIAS1 Modulate Insoluble Mutant Huntingtin Protein Accumulation (2013) (96)
- A cosmid contig and high resolution restriction map of the 2 megabase region containing the Huntington's disease gene (1993) (95)
- Hsp27 overexpression in the R6/2 mouse model of Huntington's disease: chronic neurodegeneration does not induce Hsp27 activation. (2007) (91)
- Amyloid-like inclusions in Huntington’s disease (2000) (89)
- A novel G protein-coupled receptor kinase gene cloned from 4p16.3. (1992) (85)
- Dysfunction of the CNS-Heart Axis in Mouse Models of Huntington's Disease (2014) (85)
- Alterations in the Mouse and Human Proteome Caused by Huntington’s Disease* (2002) (82)
- From neuronal inclusions to neurodegeneration: neuropathological investigation of a transgenic mouse model of Huntington's disease. (1999) (82)
- Abnormal Phosphorylation of Synapsin I Predicts a Neuronal Transmission Impairment in the R6/2 Huntington's Disease Transgenic Mice (2002) (79)
- Inhibition of Polyglutamine Aggregation in R6/2 HD Brain Slices—Complex Dose–Response Profiles (2001) (78)
- FAN1 modifies Huntington’s disease progression by stabilizing the expanded HTT CAG repeat (2018) (78)
- Isolation of a further anonymous informative DNA sequence from chromosome seven closely linked to cystic fibrosis. (1986) (76)
- Early and transient alteration of adenosine A2A receptor signaling in a mouse model of Huntington disease (2006) (76)
- A Large Number of Protein Expression Changes Occur Early in Life and Precede Phenotype Onset in a Mouse Model for Huntington Disease*S (2009) (76)
- Complex patterns of linkage disequilibrium in the Huntington disease region. (1991) (75)
- Gastrointestinal dysfunction contributes to weight loss in Huntington's disease mice (2011) (75)
- Transgenic Mice in the Study of Polyglutamine Repeat Expansion Diseases (1998) (74)
- TR-FRET-based duplex immunoassay reveals an inverse correlation of soluble and aggregated mutant huntingtin in huntington's disease. (2012) (73)
- Frequency of nuclear mutant huntingtin inclusion formation in neurons and glia is cell‐type‐specific (2016) (71)
- Defined physical limits of the Huntington disease gene candidate region. (1991) (71)
- Striking changes in anxiety in Huntington's disease transgenic mice (1998) (71)
- Genetic Knock-Down of HDAC7 Does Not Ameliorate Disease Pathogenesis in the R6/2 Mouse Model of Huntington's Disease (2009) (70)
- Evaluation of the benzothiazole aggregation inhibitors riluzole and PGL-135 as therapeutics for Huntington's disease (2006) (70)
- Reduction of GnRH and infertility in the R6/2 mouse model of Huntington's disease (2005) (69)
- Partial resistance to malonate‐induced striatal cell death in transgenic mouse models of Huntington's disease is dependent on age and CAG repeat length (2001) (65)
- The Ubiquitin-Proteasome Reporter GFPu Does Not Accumulate in Neurons of the R6/2 Transgenic Mouse Model of Huntington's Disease (2009) (64)
- Transgenic models of Huntington's disease. (1997) (63)
- HDAC4-Myogenin Axis As an Important Marker of HD-Related Skeletal Muscle Atrophy (2015) (61)
- Regional localization of the gene coding for human brain nitric oxide synthase (NOS1) to 12q24.2-->24.31 by fluorescent in situ hybridization. (1993) (61)
- A yeast artificial chromosome telomere clone spanning a possible location of the Huntington disease gene. (1990) (61)
- Experimental therapeutics in Huntington's disease: are models useful for therapeutic trials? (2003) (60)
- Amyloid, prions, and other protein aggregates (2000) (60)
- Genetic Knock-Down of Hdac3 Does Not Modify Disease-Related Phenotypes in a Mouse Model of Huntington's Disease (2012) (59)
- Identification of an HD patient with a (CAG)180 repeat expansion and the propagation of highly expanded CAG repeats in lambda phage (1997) (59)
- Inclusion formation in Huntington's disease R6/2 mouse muscle cultures (2003) (58)
- Characterization of a yeast artificial chromosome contig spanning the Huntington's disease gene candidate region (1992) (56)
- The organization of the human complement factor I gene (IF): a member of the serine protease gene family. (1994) (55)
- Optimisation of region-specific reference gene selection and relative gene expression analysis methods for pre-clinical trials of Huntington's disease (2008) (55)
- A common gene expression signature in Huntington’s disease patient brain regions (2014) (55)
- A human single-chain Fv intrabody preferentially targets amino-terminal huntingtin fragments in striatal models of Huntington's disease (2005) (54)
- Microdissection of and microcloning from the short arm of human chromosome 2 (1986) (53)
- Correlations of Behavioral Deficits with Brain Pathology Assessed through Longitudinal MRI and Histopathology in the R6/2 Mouse Model of HD (2013) (52)
- Aberrantly spliced HTT, a new player in Huntington’s disease pathogenesis (2013) (51)
- Characterisation of immune cell function in fragment and full-length Huntington's disease mouse models (2014) (51)
- Arfaptin 2 regulates the aggregation of mutant huntingtin protein (2002) (50)
- A zinc-finger gene ZNF141 mapping at 4p16.3/D4S90 is a candidate gene for the Wolf-Hirschhorn (4p-) syndrome. (1993) (48)
- Dynamic recruitment of active proteasomes into polyglutamine initiated inclusion bodies (2014) (47)
- Downregulation of cannabinoid receptor 1 from neuropeptide Y interneurons in the basal ganglia of patients with Huntington's disease and mouse models (2013) (46)
- Stall in Canonical Autophagy-Lysosome Pathways Prompts Nucleophagy-Based Nuclear Breakdown in Neurodegeneration (2017) (45)
- mHTT Seeding Activity: A Marker of Disease Progression and Neurotoxicity in Models of Huntington's Disease. (2018) (44)
- Regulatory mechanisms of incomplete huntingtin mRNA splicing (2018) (44)
- Mapping of cosmid clones in Huntington's disease region of chromosome 4 (1991) (42)
- HAP1‐huntingtin interactions do not contribute to the molecular pathology in Huntington's disease transgenic mice (1998) (40)
- Implantation of undifferentiated and pre-differentiated human neural stem cells in the R6/2 transgenic mouse model of Huntington’s disease (2012) (40)
- Correlations of Behavioral Deficits with Brain Pathology Assessed through Longitudinal MRI and Histopathology in the R6/1 Mouse Model of Huntington’s Disease (2013) (39)
- Depletion of rabphilin 3A in a transgenic mouse model (R6/1) of Huntington's disease, a possible culprit in synaptic dysfunction (2005) (39)
- Juvenile huntington's disease and other trinucleotide repeat disorders (2009) (38)
- Oral Administration of the Pimelic Diphenylamide HDAC Inhibitor HDACi 4b Is Unsuitable for Chronic Inhibition of HDAC Activity in the CNS In Vivo (2012) (38)
- The human homeobox gene HOX7 maps to chromosome 4p16.1 and may be implicated in Wolf-Hirschhorn syndrome (1990) (38)
- Mapping DNA sequences in a human X-chromosome deletion which extends across the region of the Duchenne muscular dystrophy mutation. (1985) (38)
- Cloning of the α–adducin gene from the Huntington's disease candidate region of chromosome 4 by exon amplification (1992) (37)
- The telomeric 60 kb of chromosome arm 4p is homologous to telomeric regions on 13p, 15p, 21p, and 22p. (1992) (35)
- CalDAG-GEFI down-regulation in the striatum as a neuroprotective change in Huntington's disease. (2010) (35)
- Genetic Deletion of Transglutaminase 2 Does Not Rescue the Phenotypic Deficits Observed in R6/2 and zQ175 Mouse Models of Huntington's Disease (2014) (35)
- Contesting the dogma of an age-related heat shock response impairment: implications for cardiac-specific age-related disorders (2014) (35)
- The direct screening of cosmid libraries with YAC clones. (1991) (34)
- A long-range restriction map encompassing the cystic fibrosis locus and its closely linked genetic markers. (1988) (33)
- HDAC4 Does Not Act as a Protein Deacetylase in the Postnatal Murine Brain In Vivo (2013) (32)
- Mouse Models of Huntington's Disease. (2018) (32)
- Detection of polyglutamine aggregation in mouse models. (1999) (31)
- Changes in GAD67 mRNA expression evidenced by in situ hybridization in the brain of R6/2 transgenic mice (2003) (30)
- The Huntington's Disease-Related Cardiomyopathy Prevents a Hypertrophic Response in the R6/2 Mouse Model (2014) (29)
- Loss of cortical and thalamic neuronal tenascin‐C expression in a transgenic mouse expressing exon 1 of the human Huntington disease gene (2001) (28)
- SIRT1 Activity Is Linked to Its Brain Region-Specific Phosphorylation and Is Impaired in Huntington’s Disease Mice (2016) (28)
- Transgenic mouse models of neurodegenerative disease caused by CAG/polyglutamine expansions. (1997) (28)
- Phenotype onset in Huntington’s disease knock‐in mice is correlated with the incomplete splicing of the mutant huntingtin gene (2019) (27)
- Meso scale discovery-based assays for the detection of aggregated huntingtin (2019) (26)
- New DNA markers in the Huntington's disease gene candidate region (1991) (26)
- The polyubiquitin Ubc gene modulates histone H2A monoubiquitylation in the R6/2 mouse model of Huntington's disease (2009) (26)
- Intranuclear inclusions in subtypes of striatal neurons in Huntington's disease transgenic mice. (1999) (26)
- Aberrant processing of the Fugu HD (FrHD) mRNA in mouse cells and in transgenic mice. (1997) (24)
- Subcellular Localization And Formation Of Huntingtin Aggregates Correlates With Symptom Onset And Progression In A Huntington’S Disease Model (2020) (24)
- Expanded glutamines and neurodegeneration--a gain of insight. (1996) (24)
- Systematic interaction network filtering identifies CRMP1 as a novel suppressor of huntingtin misfolding and neurotoxicity (2015) (24)
- TBK1 phosphorylates mutant Huntingtin and suppresses its aggregation and toxicity in Huntington's disease models (2020) (23)
- Live-cell super-resolution microscopy reveals a primary role for diffusion in polyglutamine-driven aggresome assembly (2018) (23)
- HSF1-dependent and -independent regulation of the mammalian in vivo heat shock response and its impairment in Huntington's disease mouse models (2017) (23)
- Caspase-6 does not contribute to the proteolysis of mutant huntingtin in the HdhQ150 knock-in mouse model of Huntington’s disease (2012) (23)
- Transgenic models of Huntington's disease. Hum Mol Genet 6:1633-1637 (1997) (22)
- Fragments of HdhQ150 Mutant Huntingtin Form a Soluble Oligomer Pool That Declines with Aggregate Deposition upon Aging (2012) (22)
- Polyglutamine expansion and Huntington's disease. (1998) (21)
- Novel Isoforms of Heat Shock Transcription Factor 1, HSF1γα and HSF1γβ, Regulate Chaperone Protein Gene Transcription* (2014) (20)
- Huntington's disease: Exploiting expression (2001) (20)
- The polyglutamine diseases (2002) (19)
- Myostatin inhibition prevents skeletal muscle pathophysiology in Huntington’s disease mice (2017) (19)
- MEF2 impairment underlies skeletal muscle atrophy in polyglutamine disease (2020) (18)
- The isolation of cDNAs within the Huntington disease region by hybridisation of yeast artificial chromosomes to a cDNA library. (1993) (17)
- Radiation hybrid map spanning the Huntington disease gene region of chromosome 4. (1992) (17)
- One Misfolded Protein Allows Others to Sneak By (2006) (17)
- Huntington’s Disease (2014) (17)
- Disruption to schizophrenia-associated gene Fez1 in the hippocampus of HDAC11 knockout mice (2017) (16)
- FAN1 controls mismatch repair complex assembly via MLH1 retention to stabilize CAG repeat expansion in Huntington’s disease (2021) (16)
- Expression of mutant exon 1 huntingtin fragments in human neural stem cells and neurons causes inclusion formation and mitochondrial dysfunction (2020) (16)
- Further data supporting linkage between cystic fibrosis and the met oncogene and haplotype analysis with met and pJ3.11. (1986) (14)
- Faculty Opinions recommendation of Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. (2001) (14)
- Mouse models of triplet repeat diseases (2006) (14)
- Correlations of Behavioral Deficits with Brain Pathology Assessed through Longitudinal MRI and Histopathology in the HdhQ150/Q150 Mouse Model of Huntington’s Disease (2017) (13)
- In Vivo Profiling Reveals a Competent Heat Shock Response in Adult Neurons: Implications for Neurodegenerative Disorders (2015) (12)
- RNA Related Pathology in Huntington's Disease. (2018) (12)
- Erratum: SIRT1 Activity is linked to its brain region-specific phosphorylation and is impaired in huntington's disease mice (PLoS ONE (2016) 11:1 (e0145425) DOI: 10.1371/journal.pone.0145425) (2016) (12)
- Mouse models of triplet repeat diseases. (2006) (11)
- Reducing Igf-1r Levels Leads To Paradoxical and Sexually Dimorphic Effects in HD Mice (2014) (11)
- Uninterrupted CAG repeat drives striatum-selective transcriptionopathy and nuclear pathogenesis in human Huntingtin BAC mice (2022) (11)
- In vivo neutralization of the protagonist role of macrophages during the chronic inflammatory stage of Huntington’s disease (2018) (11)
- Neuropsychiatry and Neuropsychology (2014) (11)
- Silencing Srsf6 does not modulate incomplete splicing of the huntingtin gene in Huntington’s disease models (2020) (11)
- Characterization of Gastric Mucosa Biopsies Reveals Alterations in Huntington's Disease (2015) (11)
- Inhibition of tumour necrosis factor alpha in the R6/2 mouse model of Huntington’s disease by etanercept treatment (2019) (11)
- Ablation of kynurenine 3-monooxygenase rescues plasma inflammatory cytokine levels in the R6/2 mouse model of Huntington’s disease (2021) (10)
- Embryonic Mutant Huntingtin Aggregate Formation in Mouse Models of Huntington’s Disease (2016) (10)
- The PDE1/5 Inhibitor SCH-51866 Does Not Modify Disease Progression in the R6/2 Mouse Model of Huntington’s Disease (2014) (10)
- Huntington's disease: In reverse gear (2000) (9)
- Extensive Expression Analysis of Htt Transcripts in Brain Regions from the zQ175 HD Mouse Model Using a QuantiGene Multiplex Assay (2019) (9)
- Cystic fibrosis linkage exclusion data. (1986) (9)
- Transgenic Mouse Models of Huntington’s Disease (2000) (8)
- False-negative result for Huntington's disease mutation (1994) (8)
- HSF 1-dependent and-independent regulation of the mammalian in vivo heat shock response and its impairment in Huntington ' s disease mouse models (2017) (7)
- Small, Seeding-Competent Huntingtin Fibrils Are Prominent Aggregate Species in Brains of zQ175 Huntington’s Disease Knock-in Mice (2021) (7)
- Monitoring aggregate formation in organotypic slice cultures from transgenic mice. (2004) (7)
- Development of novel bioassays to detect soluble and aggregated Huntingtin proteins on three technology platforms (2021) (6)
- M09 Myostatin Inhibition as a Novel Approach to Targeting Muscle Pathology in HD (2014) (6)
- Distribution of trinucleotide repeat sequences across a 2 Mbp region containing the Huntington's disease gene. (1994) (6)
- Transcript map of the human chromosome 4p16.3 consisting of 627 cDNA clones derived from 1 Mb of the Huntington's disease locus. (1996) (6)
- Hunting in the calm before the storm (2000) (6)
- Exon trapping and sequence-based methods of gene finding in transcript mapping of human 4p 16.3 (1997) (5)
- Use of high-content imaging to quantify transduction of AAV-PHP viruses in the brain following systemic delivery (2021) (5)
- HAP 1-huntingtin interactions do not contribute to the molecular pathology in Huntington ' s disease transgenic mice (1998) (5)
- Biochemical and genetic exclusion of calmodulin as the site of the basic defect in cystic fibrosis (1987) (5)
- Correlative light and electron microscopy suggests that mutant huntingtin dysregulates the endolysosomal pathway in presymptomatic Huntington’s disease (2021) (5)
- Current protocols in human genetics: edited by Nicholas C. Dracopoli et al. Current Protocols, 1994. $295.00 loose leaf (750 pages) ISBN 0 471 03420 7 (1995) (4)
- Generation of high-density DNA markers from yeast artificial chromosome DNA by single unique primer-polymerase chain reaction. (1993) (4)
- Isolation of YAC ends by plasmid rescue. (1996) (4)
- A10 SIRT2 inhibition achieves neuroprotection by decreasing sterol biosynthesis (2010) (4)
- Murine models of Huntington's Disease (1998) (4)
- Juvenile Huntington’s disease and mouse models of Huntington’s disease (2009) (3)
- The heat shock response, determined by QuantiGene multiplex, is impaired in HD mouse models and not caused by HSF1 reduction (2021) (3)
- B38 The effect of Hdac4 reduction post-weaning on hd-related phenotypes in R6/2 mice (2016) (3)
- Chapter 14 - Molecular Pathogenesis and Therapeutic Targets in Huntington's Disease (2006) (2)
- Molecular Approaches to identify the cystic fibrosis gene defect (1987) (2)
- TBK1 regulates autophagic clearance of soluble mutant huntingtin and inhibits aggregation/toxicity in different models of Huntington’s disease (2019) (2)
- The application of molecular genetics to the study of the basic defect causing cystic fibrosis. (1987) (2)
- In vivo magnetic resonance studies in a transgenic mouse model of Huntington's disease. (2002) (2)
- Genetic deletion of S6k1 does not rescue the phenotypic deficits observed in the R6/2 mouse model of Huntington’s disease (2019) (2)
- University of Dundee UBQLN 2 mediates autophagy-independent protein aggregate clearance by the proteasome (2)
- Alternative processing of human HTT mRNA with implications for Huntington’s disease therapeutics (2022) (2)
- P3-377: A novel pathogenic pathway of immune activation detectable before cinical onset in Huntington's disease (2008) (1)
- Transglutaminase 6 Is Colocalized and Interacts with Mutant Huntingtin in Huntington Disease Rodent Animal Models (2021) (1)
- Treatment Efficacy of Transplanted Human Striatal Neural Stem/Progenitor Cells in the R6/2 Mouse Model of Huntington's Disease (2010) (1)
- A Comprehensive, Multidisciplinary Description of the Progressive Pathology Exhibited by the R6/2 Mouse Model of Huntington's Disease (2010) (1)
- Genetic knock-down of HDAC 4 improves motor impairment in the R6/2 mouse model of Huntington's disease (2008) (1)
- D21 Analysis of blood and CSF biomarkers in mouse models of Huntington’s disease (2022) (1)
- RFLP for D4S12, an anonymous single copy genomic clone at 4pter-4q26 [HGM8 provisional no. D4S12]. (1985) (1)
- Molecular genetics and the basic defect causing cystic fibrosis. (1986) (1)
- B23 Immune dysfunction in HD human myeloid cells is caused by NFκB pathway dysregulation and is reversed by lowering HTT levels (2012) (1)
- B44 The Cns-heart Axis Is A Source Of Cardiac Dysfunction In Mouse Models Of Huntington’s Disease (2014) (1)
- The Huntington disease gene--still a needle in a haystack? (1993) (1)
- Molecular Pathology of Huntington's Disease: Animal Models and Nuclear Mechanisms (1999) (1)
- Inhibition of tumour necrosis factor alpha in the R6/2 mouse model of Huntington’s disease by etanercept treatment (2019) (0)
- Ex vivo 100 μm isotropic diffusion MRI‐based tractography of connectivity changes in the end‐stage R6/2 mouse model of Huntington's disease (2022) (0)
- short arm of human chromosome 2. Microdissection of and microcloning from the (2013) (0)
- B27 Abnormal bioenergetics in inclusion-containing mutant HTT exon 1 primary human neurons (2016) (0)
- Generation and characterisation of mouse embryonic stem cell lines for the study of HuntingtonG (2011) (0)
- A31 The development of translational biomarkers of neuroinflammation in a mouse model of huntington’s disease (2018) (0)
- Dietary creatine supplementation in a mouse model of Huntington's disease. (2002) (0)
- F05 Mutant huntingtin fragmentation in immune cells tracks Huntington's disease progression (2012) (0)
- Correction: SIRT1 Activity Is Linked to Its Brain Region-Specific Phosphorylation and Is Impaired in Huntington's Disease Mice (2016) (0)
- Myostatin inhibition prevents skeletal muscle pathophysiology in Huntington’s disease mice (2017) (0)
- Neurobiology of Disease Dysfunction of the Cholesterol Biosynthetic Pathway in Huntington ’ s Disease (0)
- Combined Proteome and Transcriptome Analysis of Alterations in the Mouse Brain Caused by Huntington?s Disease (2005) (0)
- Early detection of exon 1 huntingtin aggregation in zQ175 brains by molecular and histological approaches (2023) (0)
- A03 Alternative processing of human HTT MRNA in YAC128 mice: implications for Huntington’s disease therapeutics (2022) (0)
- A04 The role of splicing factor SRSF6 in incomplete splicing of the HTT transcript (2018) (0)
- A large number of protein expression changes occur early in life and precede phenotype onset in different animal models for Huntington's disease (2009) (0)
- B8 Ablation of p62 modulates levels of soluble and aggregated mutant huntingtin and delays end-stage disease in R6/2 mice (2016) (0)
- B3 Comparison of the effect of a pure CAG repeat and mixed cagcaa repeat on the extent to which the htt gene is aberrantly spliced in knock-in mice (2016) (0)
- L3 Systemic administration of a novel AAV variant results in widespread and efficient gene transfer in R6/2 mice (2016) (0)
- Regulatory mechanisms of incomplete huntingtin mRNA splicing (2018) (0)
- A03 Regulatory mechanisms of incomplete HTT MRNA splicing in huntington’s disease (2018) (0)
- B6 Super-resolution fluorescence imaging of the seeding and polymerizatoin of the huntingtin exon 1 protein (2016) (0)
- Model depicting the mechanism by which mutant huntingtin causes cardiac dysfunction in murine HD hearts. (2014) (0)
- A21 Transcriptional dysregulation is caused by the accumulation of detergent insoluble HTT aggregates in the nucleus (2018) (0)
- B24 Assessment of immune system activation status during the course of disease in huntington’s disease mouse model (2016) (0)
- A16 The temporal and spatial appearance of huntingtin aggregates in the brains of the ZQ175 mouse model of huntington’s disease (2018) (0)
- B19 Development of in vitro models to investigate the pathogenesis of huntington’s disease and screen for therapeutic agents (2018) (0)
- Disruption to schizophrenia-associated gene Fez1 in the hippocampus of HDAC11 knockout mice (2017) (0)
- Reduction in PA28αβ activation in HD mouse brain correlates to increased mHTT aggregation in cell models (2022) (0)
- B4 Detection of the aberrantly spliced exon 1 – intron 1 htt mRNA in HD patient post mortem brain tissue and fibroblast lines (2016) (0)
- A18 Investigating the mechanisms of the heat shock response impairment in huntington’s disease (2018) (0)
- A common gene expression signature in Huntington’s disease patient brain regions (2014) (0)
- C02 FAN1 controls cag repeat expansion in huntington’s disease by dual functions, MLH1 retention and nuclease activity (2021) (0)
- Identification of two novel heat shock factor isoforms - HSF1 isoform ratio regulates the level of transcription of heat shock protein genes.* (2014) (0)
- Wiley Encyclopedia of Molecular Medicine Volume 3 (H-M) (2002) (0)
- In vivo, longitudinal, 1H Magnetic Resonance Spectroscopy in a transgenic mouse model of Huntington's Disease (2002) (0)
- D05 Development and optimisation of a quantigene assay to measure HTT transcripts levels and investigate the efficiency of lowering htt in vivo (2018) (0)
- Erratum: Valenza et al., “Dysfunction of the Cholesterol Biosynthetic Pathway in Huntington's Disease” (2020) (0)
- The pathogenic exon 1 HTT protein is produced by incomplete splicing in Huntington’s disease patients (2017) (0)
- FurtherDataSupporting LinkagebetweenCystic Fibrosis andthemetOncogene andHaplotype Analysis withmetandpJ3.11 (1986) (0)
- RFLP for pHM20 (D2S12), an anonymous DNA sequence localised to 2p23-2pter. (1987) (0)
- Experimental therapeutics in mouse models of Huntington's disease. (2005) (0)
- D03 Novel bioassays to detect soluble and aggregated isoforms of the huntingtin protein on three technology platforms (2022) (0)
- Progress towards identification of the gene defect in cystic fibrosis (1987) (0)
- Intranuclear Neuronal Inclusions: A novel marker in Huntington's disease which correlates with CAG triplet repeat length (1998) (0)
- In vivo neutralization of the protagonist role of macrophages during the chronic inflammatory stage of Huntington’s disease (2018) (0)
- Mutant HTT seeding activity: a marker of disease progression and neurotoxicity in models of Huntington’s disease (2018) (0)
- The Hunt in Huntington: What Causes Toxicity? (2009) (0)
- The molecular basis of Huntington's disease and polyglutamine disorders (2000) (0)
- HSF1-dependent and -independent regulation of the mammalian in vivo heat shock response and its impairment in Huntington's disease mouse models (2017) (0)
- Analysis of the transgenome of MET transfectant cell lines reveals that MET activation is accompanied by an interstitial insertion (1990) (0)
- Absolute Quantification of Brain metabolites in a Mouse model of Huntington's Disease (2003) (0)
- The use of quantitative real-time PCR to characterise transcriptional dysregulation in mouse models of Huntington's disease (2008) (0)
- A20 A role for transglutaminase 6 in hd pathology (2018) (0)
- THE EFFECT OF HDAC 4 REDUCTION POST-WEANING ON HD-RELATED PHENOTYPES IN R 6 / 2 MICE (2019) (0)
- Cloning of human telomeres in Saccharomyces cerevisiae. (1996) (0)
- Transgenic models of HD (1997) (0)
- Characterization of the protein component of Methanococcus jannaschii RNase P (2001) (0)
- Molecular Approaches Toward the Isolation of the Huntington’s Disease Gene (1990) (0)
- A11 The temporal and spatial appearance of HTT aggregation in the brains of zQ175 mice (2022) (0)
- C01 R6/2 Mice With A 90q Repeat Expansion Show Earlier Aggregate Pathology In Brain (2014) (0)
- A large number of protein expression changes in a mouse model of Huntington's disease early in life precede overt disease symptoms (2008) (0)
- C02 Molecular Analysis Of The Zq175 Knock-in Mouse Model (2014) (0)
- Correlative light and electron microscopy suggests that mutant huntingtin dysregulates the endolysosomal pathway in presymptomatic Huntington’s disease (2021) (0)
- A17 Myeloid cell function in mouse models of Huntington's disease (2010) (0)
- DEFINITION OF THE PHYSICAL AND GENETIC LIMITS OF THE HUNTINGTONS-DISEASE GENE CANDIDATE REGION AND PROGRESS TOWARDS ITS ISOLATION AS A YAC CONTIG (1991) (0)
- Overall visit frequency detected in the PhenoCube system as a function of genotype, age and light cycle phase in animals from the zQ175×TG2 KO line. (2014) (0)
- A12 HDAC4 interacts with huntington and HDAC4 reduction decreases cytoplamsic aggregation and rescues synaptic dysfunction in HD mouse models (2012) (0)
- Erratum: Heber et al., “Mice with Combined Gene Knock-Outs Reveal Essential and Partially Redundant Functions of Amyloid Precursor Protein Family Members” (2020) (0)
- B09 Caspase-6 does not contribute to the proteolysis of mutant huntingtin in the HDHQ150 knock-in mouse model of Huntington's disease (2012) (0)
- Central nervous system diseases. (1999) (0)
- Reply (2003) (0)
- Correction: SIRT2 Ablation Has No Effect on Tubulin Acetylation in Brain, Cholesterol Biosynthesis or the Progression of Huntington’s Disease Phenotypes In Vivo (2021) (0)
- D11 Expression Analysis Of Genes Coding For Pet Ligands In HD Mouse Models (2014) (0)
- D08 A Holistic Network Analysis Of Gene Expression Data In Huntington’s Disease Patients Reveals A Common Signature Of Transcriptional Dysregulation (2014) (0)
- Absolute quantification of metabolites using a surface coil and an external reference in mouse brain. (2002) (0)
- B03 Analysis of a Huntington’s disease knock-in mouse model designed to prevent the generation of the exon 1 HTT protein (2022) (0)
- A19 Peripheral Pathologies in Mouse Models of HD and the Inhibtion of Myostatin Signalling as a Possible Therapeutic Target (2014) (0)
- Implantation of undifferentiated and pre-differentiated human neural stem cells in the R6/2 transgenic mouse model of Huntington’s disease (2012) (0)
- A4 Development of disease modifying therapies in Huntington's disease (2012) (0)
- Dynamics of somatic CAG instability in Huntington's disease. (2005) (0)
- B10 Inclusion formation in mutant HTT exon 1 expressing human neuronal cells (2016) (0)
- B17 Establishing a neural progenitor cell model of huntington’s disease (2018) (0)
- Huntington's disease: molecular pathogenesis and therapeutic approaches. (2006) (0)
- Chronic administration of isoproterenol causes a significant transcriptional deregulation of many Hdacs and Sirtuins. (2014) (0)
- Insights into the molecular pathogenesis of Huntington's disease (2001) (0)
- Correlative light and electron microscopy reveals that mutant huntingtin dysregulates the endolysosomal pathway in presymptomatic Huntington’s disease (2021) (0)
- PhysiologyDavid and Wolfgang-Michael Franz From Pluripotency to Distinct Cardiomyocyte Subtypes (2015) (0)
- In vivo MR studies in a transgenic mouse model of Huntington's disease (2001) (0)
This paper list is powered by the following services:
Other Resources About Gillian Bates
What Schools Are Affiliated With Gillian Bates?
Gillian Bates is affiliated with the following schools: